MOLECULAR CLONING OF UNIQUE CYTOKINES & PROTOONCOGENES

细胞因子和原癌基因是细胞凋亡的关键调节因子。 功能、生存能力、差异化和沟通。因此，在本发明中， 细胞因子现在被用于治疗许多疾病 包括癌症、自身免疫、贫血和肾衰竭。是 在不久的将来，药物可能会干扰 原癌基因也将发现临床用途。长期目标 该项目的主要目的是通过以下方法鉴定新的细胞因子和原癌基因： 一种新的亲和层析技术。通过这个过程，我们 已经构建了几个cDNA文库， 富集细胞因子和原癌基因cDNA。百分之三十五 从这个文库中随机筛选的cDNA编码已知的 细胞因子或原癌基因，而相同百分比是独特的 与已知的人类mRNA没有同源性。第一阶段的目标 项目为1）。鉴定文库中所有新的cDNA， 部分核苷酸测序和数据库搜索和2）。克隆 来自组织特异性cDNA的相应全长cDNA 图书馆.如果我们成功，我们将申请第二阶段资金， 从额外的细胞和组织来源构建新的文库， 表征我们的新型细胞因子的功能， 并开始商业化的过程 重要的新分子与成熟的制药公司。 拟定商业应用： 细胞因子和原癌基因与许多疾病有关， 包括癌症Symphony发明了一种新的克隆方法 这些基因家族的成员基于他们的后- 转录调控特征。新型细胞因子的克隆 原癌基因将为治疗提供新的靶点， 干预Symphony还开发了一个药物筛选项目 靶向转录后相互作用， 已鉴定的基因将代表潜在的靶点。

Cytokines and protooncogenes are critical modulators of cellular function, viability, differentiation and communication. As such, cytokines are now being used in the treatment of many diseases including cancer, autoimmunity, anemia and renal failure. It is likely that in the near future drugs capable of interfering with protooncogenes will also find clinical use. The long term objective of this project is to identify new cytokines and protooncogenes by a novel affinity chromatographic technique. Using this process, we have constructed several cDNA libraries which are substantially enriched for cytokine and protooncogene cDNAs. Thirty-five percent of randomly screened cDNAs from this library code for known cytokines or protooncogenes while an equal percentage are unique without homology to known human mRNAs. The aims of this Phase I project are to 1). identify all novel cDNAs within the library by partial nucleotide sequencing and database search and 2). clone the corresponding full-length cDNAs from tissue specific cDNA libraries. If we are successful, we will apply for Phase 2 funds to construct new libraries from additional cell and tissue sources, characterize the functionality of our novel cytokines and protooncogenes and begin the commercialization process for these important new molecules with established pharmaceutical companies. PROPOSED COMMERCIAL APPLICATION: Cytokines and protooncogenes are implicated in numerous diseases, including cancer. Symphony has developed a novel method of cloning members of these gene families based upon their post- transcriptional regulatory features. The cloning of novel cytokines and protooncogenes will provide new targets for therapeutic intervention. Symphony has also developed a drug screening program targeting post-transcriptional interactions for which these newly identified genes would represent potential targets.